Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradu
| Current Price | ₹812.30 |
|---|---|
| Market Cap | ₹1,714 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 26.1 |
| Return on Equity | 12.23% |
| 52-Week Range | ₹697.40 – ₹1,097.90 |
| Beta (1Y) | 0.49 |
| Dividend Yield | 0.78% |
1. Pharmaceuticals-100%
Windlas Biotech Ltd is trading at ₹812.30, with a market capitalisation of ₹1,714 Cr.
Windlas Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Windlas Biotech Ltd has a P/E of 26.1 and a return on equity of 12.23%.